Pharmacologic inhibitors of MKK1 and MKK2.
Ahn
N G
NG
Department of Chemistry and Biochemistry, Howard Hughes Medical Institute, University of Colorado, Boulder, Colorado 80309, USA.
Nahreini
T S
TS
Tolwinski
N S
NS
Resing
K A
KA
D016475:3T3 Cells; D000818:Animals; D000918:Antibody Specificity; D001562:Benzimidazoles / Q000737:chemistry / Q000494:pharmacology; D002070:Butadienes / Q000737:chemistry / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D020014:K562 Cells; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; D048728:MAP Kinase Kinase Kinase 1; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D009570:Nitriles / Q000737:chemistry / Q000494:pharmacology; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014162:Transfection
D001562:Benzimidazoles; D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; C109202:PD 58491; D011994:Recombinant Proteins; C113580:U 0126; C482128:MAP2K2 protein, human; D011505:Protein-Tyrosine Kinases; D017346:Protein Serine-Threonine Kinases; D048728:MAP Kinase Kinase Kinase 1; C482576:MAP3K1 protein, human; C482578:Map3k1 protein, mouse; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; C482125:MAP2K1 protein, human; C482127:Map2k1 protein, mouse; D020929:Mitogen-Activated Protein Kinase Kinases